

Margo Monroe, PhD

PRINCIPAL

617-248-5004

✓ mmonroe@choate.com

Dr. Margo Monroe counsels start-ups, private and public companies, venture capitals, and worldclass academic research institutions in a wide range of technologies at the intersection of life sciences and engineering, with an emphasis on engineered cell or gene-editing based therapies, diagnostics, and targeted delivery technologies.

Margo helps clients quickly understand, evaluate, and respond to patent issues that arise in the context of business deals and/or during R&D of new products and technologies, while also securing strong worldwide patent protection for assets, including those whose major uses provide unique business opportunities. Margo has advised clients through various phases of due diligence, including mergers and acquisitions, partnerships, fundraising, and IPOs, many of which have required strategic navigation of complex technical landscapes and emerging legal issues. Margo also counsels clients with respect to third party risks, IP landscape issues, and freedom-to-operate analyses to assist with R&D and/or business decisions.

Her clients appreciate her ability to distill complex data into understandable and actionable formats.

Admissions

- Massachusetts
- · U.S. Patent & Trademark Office

Representative Engagements

Strategic Patent Counseling: IP Due Diligence, Landscape Analysis, and Prosecution

- Represents venture capital groups in assessing IP landscape relating to novel strategies for CAR-T and nanoparticle delivery platforms, including negotiating option and license agreements, and partnerships with research laboratories and companies world-wide.
- Represents gene editing company in CRISPR technology from start-up through IPO through restructuring
 of assets, including various freedom-to-operate, IP due diligences, landscape analyses, and SEC filings.
- Represents gene therapy company in the hearing disorders space from start-up through IPO through acquisition of assets, including various freedom-to-operate, IP due diligences, landscape analyses, and SEC filings.
- Represents a start-up viral delivery company to navigate a complex gene therapy patent landscape and develop an exclusivity proposition attractive to large pharmaceutical partners.
- · Represents a world-class academic research institution from building global, layered protection of

Focus Areas

Intellectual Property
IP Counseling
Private Equity and M&A
Life Sciences and
Technology

CHOATE

foundational and life-cycle management patent assets through out-licensing of patent assets to startup, including various freedom-to-operate and IP due diligences in the nanotheranostics space.

- Represents a bioinformatics and multi-omics company through multiple freedom-to-operate, diligences, and non-infringement analyses to advice on patent strategies related to computational biology tools combined with a novel next generation sequencing (NGS) assay platform.
- Represents start-up gene editing company with respect to performing landscape analyses to help inform strategic building of patent assets in complex technology space.
- Has represented nucleic acid lipid nanoparticle delivery company from start-up through acquisition, crafting an IP portfolio with layered protection of both platform technologies and key product candidates, including in support of major collaborations. Continues to represent acquiring gene editing company to maximize acquired patent assets.
- Develops life-cycle management strategies for clients to protect assets whose base composition of matter protection may be expiring before products can be commercialized.

Post Grant Proceedings

• Life sciences company in ex parte re-examination of patent directed to CRISPR technology.

Professional & Community Involvement

- · Member of the Boston Patent Law Association
- · Member of the Boston Bar Association
- · Advocate for PhDs looking for careers outside of academia